Beta
Trial Radar KI
enums.trial_summary.trial_summary_welcome
Eine Studie entspricht den Filterkriterien
Kartenansicht

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

Aktiv, nicht rekrutierend
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT06410209 untersucht Prävention im Zusammenhang mit Neoplasma des hämatopoetischen und lymphatischen Systems, Bösartige solide Neoplasie. Diese interventionsstudie der Phase 2 hat den Status aktiv, nicht rekrutierend und startete am 15. Oktober 2024. Es ist geplant, 190 Teilnehmer aufzunehmen. Durchgeführt von Children's Oncology Group wird der Abschluss für 15. September 2027 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 24. Oktober 2025 aktualisiert.
Kurzbeschreibung
This clinical trial tests the impact of a culturally-tailored home-based physical activity program on physical fitness in Hispanic or Latino/Latina adolescent and young adult (AYA) childhood cancer survivors. After treatment for cancer, some AYA survivors experience long-term effects from the cancer and its treatment including weight gain, fatigue and decreased physical fitness. Hispanic or Latino/Latina survivors may have a higher risk of these effects compared to non-Hispanics. Regular physical activity helps maintain healthy weight, energy levels and overall health. Participating in a culturally-tailored home-based physical activity program may help increase physical activity in Hispanic or Latino/Latina AYA childhood cancer survivors.
Ausführliche Beschreibung
PRIMARY OBJECTIVES:

I. Use an iterative approach to develop a culturally-tailored multilevel remote-based physical activity (PA) intervention among a total of 20 Latinx adolescent and young adult survivors of childhood cancer (AYA survivors), 8-12 whose preferred language is English and 8-12 whose preferred language is Spanish, using the StepByStep intervention as a starting point. (Stage 1) II. Conduct a randomized controlled trial (RCT) to test the potential efficacy of the culturally-tailored remote-based PA intervention (versus [vs.] Fitbit only) with respect to the primary outcome of moderate to vigorous physical activity (MVPA) measured with a research grade accelerometer over 12 weeks among a separate group of 170 Latinx AYA survivors whose preferred language is Spanish or English (n=85 per randomization arm) and who do not meet PA guidelines at baseline. The control group will receive a Fitbit only. (Stage 2)

SECONDARY OBJECTIVES:

I. Among the patients enrolled to the RCT component of the study, evaluate the potential efficacy of randomization to the intervention relative to control arm with respect to decreasing sedentary time as assessed by a research accelerometer.

II. Evaluate potential efficacy of randomization to the active intervention arm with respect to improvement in reported health-related quality of life.

EXPLORATORY OBJECTIVES:

I. Evaluate potential efficacy of randomization to the active intervention arm with respect to physiological measurements predictive of cardiometabolic health.

II. Determine the acceptability of and guidance on improving the intervention phases in preparation for a fully powered, long term RCT by conducting two rounds of post-trial qualitative interviews among selected consenting participants, n=30 for the intensive intervention phase and n=30 for the maintenance intervention phase. Preferences and barriers for an additional diet and nutrition component will also be explored.

OUTLINE:

STAGE 1: Patients wear a Fitbit physical activity tracker daily, set physical activity goals, receive text messages, and view private social media peer support group content over 7-10 days once every 3 months. Patients also wear a research grade activity measuring device over 1-3 days and participate in a one-on-one interview once every 3 months for 9 months.

STAGE 2: Patients are randomized to 1 of 2 groups.

GROUP I (INTERVENTION):

INTENSIVE PHASE: Patients wear a Fitbit physical activity tracker daily and receive weekly reminders to wear the Fitbit for 12 weeks. Patients attend weekly goal setting sessions, receive individualized physical activity goals, view and post private social media peer support group content 2-3 times weekly, and receive badges for 12 weeks.

MAINTENANCE PHASE: Patients wear a Fitbit physical activity tracker daily and set their own physical activity goals weekly for 4 weeks. Patients also receive access to the social media account and post content for 4 weeks.

GROUP II (CONTROL): Patients wear a Fitbit physical activity tracker daily for 12 weeks.

Offizieller Titel

Walking Juntos: Developing and Testing a Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors

Erkrankungen
Neoplasma des hämatopoetischen und lymphatischen SystemsBösartige solide Neoplasie
Weitere Studien-IDs
NCT-Nummer
Studienbeginn (tatsächlich)
2024-10-15
Zuletzt aktualisiert
2025-10-24
Studienende (vorauss.)
2027-09-15
Geplante Rekrutierung
190
Studientyp
Interventionsstudie
PHASE
Phase 2
Status
Aktiv, nicht rekrutierend
Primäres Ziel
Prävention
Zuteilungsmethode
Randomisiert
Interventionsmodell
Sequentiell
Verblindung
Dreifach
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
ExperimentellStage 1 (Fitbit, interview)
Patients wear a Fitbit physical activity tracker daily, set physical activity goals, receive text messages, and view private social media peer support group content over 7-10 days once every 3 months. Patients also wear a research grade activity measuring device over 1-3 days and participate in a one-on-one interview once every 3 months for 9 months.
Zielsetzung
Set physical activity goals
Interview
Participate in a one-on-one interview
Medienintervention
View private social media peer support group content
Verwendung und Bewertung von Medizinprodukten
Wear a Fitbit physical activity tracker
Verwendung und Bewertung von Medizinprodukten
Wear a research grade activity measuring device
Fragebogenverwaltung
Ancillary studies
Textnachrichtenbasierte Navigationsintervention
Receive text messages
ExperimentellStage 2, Group I (Fitbit, goal setting, peer support)
INTENSIVE PHASE: Patients wear a Fitbit physical activity tracker daily and receive weekly reminders to wear the Fitbit for 12 weeks. Patients attend weekly goal setting sessions, receive individualized physical activity goals, view and post private social media peer support group content 2-3 times weekly, and receive badges for 12 weeks. MAINTENANCE PHASE: Patients wear a Fitbit physical activity tracker daily and set their own physical activity goals weekly for 4 weeks. Patients also receive access to the social media account and post content for 4 weeks.
Zielsetzung
Set physical activity goals
Interview
Ancillary studies
Medienintervention
View private social media peer support group content
Verwendung und Bewertung von Medizinprodukten
Wear a Fitbit physical activity tracker
Fragebogenverwaltung
Ancillary studies
Belohnung
Receive badges
Textnachrichtenbasierte Navigationsintervention
Receive reminders
Aktives VergleichspräparatStage 2, Group II (Fitbit)
Patients wear a Fitbit physical activity tracker daily for 12 weeks.
Verwendung und Bewertung von Medizinprodukten
Wear a Fitbit physical activity tracker
Fragebogenverwaltung
Ancillary studies
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Moderate to vigorous physical activity (MVPA)
MVPA will be measured with a research grade accelerometer. Will report the mean change from baseline to the 11-12-week post randomization timepoint by trial arm alongside corresponding confidence intervals estimated under a linear mixed effects model.
Baseline to 11-12 weeks post randomization
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Sedentary time
Sedentary time will be measured with a research grade accelerometer. Will report the mean change from baseline to the 11-12-week post randomization timepoint by trial arm alongside corresponding confidence intervals estimated under a linear mixed effects model.
Baseline to 11-12 weeks post randomization
Global functioning
Global functioning will be measured using Spanish language versions of the Pediatric Quality of Life inventory (PedsQL) 4.0 Generic Core Scales. Will report the mean change from baseline to the 11-12-week post randomization timepoint by trial arm alongside corresponding confidence intervals estimated under a linear mixed effects model.
Baseline to 11-12 weeks post randomization
Physical functioning
Physical functioning will be measured using Spanish language versions of the Pediatric Quality of Life inventory (PedsQL) 4.0 Generic Core Scales. Will report the mean change from baseline to the 11-12-week post randomization timepoint by trial arm alongside corresponding confidence intervals estimated under a linear mixed effects model.
Baseline to 11-12 weeks post randomization
Social functioning
Social functioning will be measured using Spanish language versions of the Pediatric Quality of Life inventory (PedsQL) 4.0 Generic Core Scales. Will report the mean change from baseline to the 11-12-week post randomization timepoint by trial arm alongside corresponding confidence intervals estimated under a linear mixed effects model.
Baseline to 11-12 weeks post randomization
Fatigue
Fatigue will be measured using the18-item PedsQL 4.0 Multidimensional Fatigue Scale in Spanish or English. Will report the mean change from baseline to the 11-12-week post randomization timepoint by trial arm alongside corresponding confidence intervals estimated under a linear mixed effects model.
Baseline to 11-12 weeks post randomization
Eignungskriterien

Zugelassene Altersgruppen
Kind, Erwachsene
Mindestalter
15 Years
Zugelassene Geschlechter
Alle
  • Patient must be ≥ 15 years and < 21 years at the time of enrollment
  • First diagnosis of malignant neoplasm (International Classification of Diseases for Oncology [ICD-O] behavior code of "3") in first and continuous remission at the time of enrollment
  • Curative cancer treatment must have included chemotherapy (including cellular therapy) and/or radiation (including radioactive iodine). Note: Children's Oncology Group (COG) therapeutic trial participation is not required
  • Completed all chemotherapy and/or radiation therapy in the last 3-36 months. This includes completion of all oral (e.g., tyrosine kinase inhibitors) and/or maintenance chemotherapy
  • Self-report of < 420 minutes of moderate-to-vigorous physical activity per week as assessed and documented via the study-specific Physical Activity Worksheet. Note: See the case report forms packet on the COG study web page for the study specific Physical Activity Worksheet
  • Ambulatory and no known medical contraindications to increasing physical activity
  • No known significant physical or cognitive impairment that would prevent use of the electronic devices used for the protocol intervention (e.g., Fitbit, smartphone, tablet, or computer)
  • Able to read and write Spanish or English
  • Self-identify as Hispanic, Latino/Latina/Latinx

  • Patients with previous allogeneic hematopoietic stem cell transplant (HSCT) are excluded. Note: Patients with previous autologous HSCT, chimeric antigen receptor T-cell (CAR T-cell) therapy, and other cellular cancer therapies can participate as long as all other eligibility criteria are satisfied
  • Post-menarchal female patients who are pregnant or planning to become pregnant in the next year are excluded. Note: Pregnancy status can be established by clinical history with patient. Post-menarchal female patients are eligible as long as they agree to use an effective contraceptive method (including abstinence) during study participation
  • Participants who were enrolled in ALTE2031 (Step by Step) cannot enroll in ALTE2321. Participants who were enrolled in ALTE2321 Stage 1 (cultural tailoring) cannot enroll to participate in Stage 2 (RCT)
  • All patients and/or their parents or legal guardians must sign a written informed consent. Note: Informed consent may be obtained electronically/online if allowed by local site policy and institutional review board (IRB)/ Research Ethics Board (REB) of record
  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Children's Oncology Group logoChildren's Oncology Group
Keine Kontaktdaten vorhanden
51 Studienstandorte in 2 Ländern

Arizona

Banner Children's at Desert, Mesa, Arizona, 85202, United States

California

Kaiser Permanente Downey Medical Center, Downey, California, 90242, United States
City of Hope Comprehensive Cancer Center, Duarte, California, 91010, United States
Miller Children's and Women's Hospital Long Beach, Long Beach, California, 90806, United States
Valley Children's Hospital, Madera, California, 93636, United States
UCSF Benioff Children's Hospital Oakland, Oakland, California, 94609, United States
Kaiser Permanente-Oakland, Oakland, California, 94611, United States

Colorado

Children's Hospital Colorado, Aurora, Colorado, 80045, United States

Connecticut

Yale University, New Haven, Connecticut, 06520, United States

Delaware

Alfred I duPont Hospital for Children, Wilmington, Delaware, 19803, United States

District of Columbia

MedStar Georgetown University Hospital, Washington D.C., District of Columbia, 20007, United States

Florida

Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, 33908, United States
Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, 33021, United States
Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, 32207, United States
AdventHealth Orlando, Orlando, Florida, 32803, United States
Arnold Palmer Hospital for Children, Orlando, Florida, 32806, United States
Nemours Children's Hospital, Orlando, Florida, 32827, United States

Illinois

University of Illinois, Chicago, Illinois, 60612, United States

Indiana

Riley Hospital for Children, Indianapolis, Indiana, 46202, United States
Ascension Saint Vincent Indianapolis Hospital, Indianapolis, Indiana, 46260, United States

Iowa

Blank Children's Hospital, Des Moines, Iowa, 50309, United States

Maryland

Sinai Hospital of Baltimore, Baltimore, Maryland, 21215, United States

Nebraska

Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, 68114, United States
University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States

Nevada

University Medical Center of Southern Nevada, Las Vegas, Nevada, 89102, United States
Sunrise Hospital and Medical Center, Las Vegas, Nevada, 89109, United States
Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, 89135, United States
Summerlin Hospital Medical Center, Las Vegas, Nevada, 89144, United States
Renown Regional Medical Center, Reno, Nevada, 89502, United States

New Jersey

Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States

New Mexico

University of New Mexico Cancer Center, Albuquerque, New Mexico, 87106, United States

New York

Maimonides Medical Center, Brooklyn, New York, 11219, United States
Montefiore Medical Center - Moses Campus, The Bronx, New York, 10467, United States

North Carolina

Duke University Medical Center, Durham, North Carolina, 27710, United States

Oregon

Legacy Emanuel Children's Hospital, Portland, Oregon, 97227, United States

Pennsylvania

Penn State Children's Hospital, Hershey, Pennsylvania, 17033, United States

South Carolina

BI-LO Charities Children's Cancer Center, Greenville, South Carolina, 29605, United States

Tennessee

East Tennessee Childrens Hospital, Knoxville, Tennessee, 37916, United States
Saint Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States
The Children's Hospital at TriStar Centennial, Nashville, Tennessee, 37203, United States

Texas

Dell Children's Medical Center of Central Texas, Austin, Texas, 78723, United States
Driscoll Children's Hospital, Corpus Christi, Texas, 78411, United States
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States
El Paso Children's Hospital, El Paso, Texas, 79905, United States
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, 77030, United States
M D Anderson Cancer Center, Houston, Texas, 77030, United States
Children's Hospital of San Antonio, San Antonio, Texas, 78207, United States
Methodist Children's Hospital of South Texas, San Antonio, Texas, 78229, United States
University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States

Washington

Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, 99204, United States
University Pediatric Hospital, San Juan, 00926, Puerto Rico